leu011
(2)
Leucid Bio
Leucid Bio is a clinical-stage London biotech developing next-generation CAR-T cell therapies for refractory solid tumors. Spun out of King's College London in 2014 to commercialize two decades of research by Dr John Maher, the company's proprietary Lateral CAR platform redesigns the CAR receptor so its signalling domains sit laterally alongside the cell membrane - mimicking natural immune receptors to boost potency while reducing toxicity. Its lead candidate, LEU011, is an autologous NKG2D-targeting CAR-T therapy now in the Phase I/IIa AERIAL trial for refractory solid tumors.
Filippo Petti
Filippo Petti is the Chief Executive Officer of Leucid Bio, a London-based clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumours built on a proprietary lateral CAR platform spun out of two decades of King's College London research. Appointed CEO in July 2023, Petti pairs a bench-science start at OSI Pharmaceuticals with years on Wall Street as a healthcare investment banker and equity analyst, and a prior run leading Celyad Oncology as CEO and CFO. Under his watch, Leucid moved its lead asset LEU011 into the AERIAL Phase I/IIa trial, reporting early proof-of-concept in relapsed/refractory solid tumours in late 2025.